Table 2.

Demographic and therapeutic data of patients with AOSD.

Patients no.	76
Male/Female no.	26/50
Mean age ± SD (years)	47.90 ± 15.13
Age at onset (mean ± SD) (years)	39.98 ± 15.05
Age at diagnosis (mean ± SD) (years)	41.96 ± 14.49
Disease duration (median ± IQR) (years)	6.00 ± 9.00
Treatment delay (median ± IQR) (years)	3.25 ± 7.47
Previous biologics	ETN (n = 9); IFX (n = 6); ADA (n = 3); GOL (n = 1); TCZ (n = 1); RTX (n = 1)
Previous cDMARDs	MTX (n = 42); CsA (n = 18); SSZ (n = 4); LFN (n = 2); HCQ (n = 19); AZA (n = 4); CPH (n = 1); CQN (n = 2); COL (n = 2).
Concomitant cDMARDs	MTX (n = 18); CsA (n = 4); SSZ (n = 1); LFN (n = 2); HCQ (n = 7)

ADA, adalimumab; AZA, azathioprine; CQN, chloroquine; COL, colchicine; CPH, cyclophosphamide; CsA, cyclosporine; ETN, etanercept; GOL, golimumab; HCQ, hydroxychloroquine; IFX, infliximab; LFN, leflunomide; MTX, methotrexate; RTX, rituximab; SSZ, sulfasalazine; TCZ, tocilizumab AOSD, Adult onset Still disease; IQR, interquartile range; cDMARDs, conventional disease modifying anti-rheumatic drugs.